Headline:
Covid-19: Sars-CoV-2 Continues to Circulate and Evolve; Omicron XEC Remains Dominant, But New Variants Emerge
Article:
The world’s coexistence with Sars-CoV-2 continues as the virus remains a persistent presence among respiratory pathogens. While the Covid-19 pandemic has been archived, the virus continues to cause illnesses, deaths, and long Covid symptoms globally. It also continues to evolve, leading to a dynamic landscape of variants.
The World Health Organization (WHO) provides an update on the current variant situation. Omicron XEC remains the most prevalent, but the picture is more diverse and fluid than initially thought.
The Current Variant Landscape
The WHO reports that all currently circulating Sars-CoV-2 variants origin from the JN.1 lineage. The proportion of sequenced XEC cases has been increasing, while other variants of interest (JN.1) or under monitoring (KP.2, KP.3, KP.3.1.1, JN.1.18, LB.1) have seen a decline. However, several other JN.1-derived variants are emerging, such as LP.8.1, NP.1, and LF.7.2, which are currently under monitoring and characterization.
The future trajectory of these variants, including their mutations and antigen characteristics, is challenging to predict. The potential impact on public health remains unknown.
Targeting the JN.1 Family for Future Vaccines
Given the virus’s ongoing circulation and evolution, vaccination remains a crucial public health measure. The WHO recommends continuing to offer vaccines targeting the JN.1 variant family. The WHO’s Technical Advisory Group on Covid-19 Vaccine Composition advises maintaining the use of a monovalent vaccine targeting the JN.1 lineage to induce broader neutralizing antibody responses against circulating variants, including XEC, KP.3.1.1, and their descendant variants.
The goal of updating the vaccine antigen composition is to enhance immune responses against circulating variants. In the meantime, vaccination should not be delayed in anticipation of updated vaccines. Any Covid-19 vaccine listed for emergency use or prequalified by the WHO can continue to be used in vaccination programs.
While the coronavirus continues to circulate and mutate, surveilling its evolution and population immune responses will remain crucial. The WHO’s technical advisory group will continue to monitor the situation and provide updates as needed.
Sources:
- World Health Organization
- Gisaid
